PODD logo

PODD

Insulet Corporation

$256.62
+$0.81(+0.32%)
43
Overall
30
Value
33
Tech
68
Quality
Market Cap
$20.84B
Volume
1.07M
52W Range
$230.05 - $354.88
Target Price
$372.79

Company Overview

Mkt Cap$20.84BPrice$256.62
Volume1.07MChange+0.32%
P/E Ratio49.8Open$256.91
Revenue$2.1BPrev Close$255.81
Net Income$418.3M52W Range$230.05 - $354.88
Div YieldN/ATarget$372.79
Overall43Value30
Quality68Technical33

No chart data available

About Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Sector: Healthcare
Industry: Medical Devices

Latest News

Insulet Completes Key Omnipod 5 SmartAdjust 2.0 Study, Setting Up Next Growth Phase

Insulet ($PODD) announced an update on their ongoing clinical study. Study Overview Insulet’s latest clinical study, titled “Safety and Effectivene...

TipRanks Clinical-Trials-Auto-Generated Newsdesk12 days ago

Analysts Conflicted on These Healthcare Names: Insulet (PODD) and Gilead Sciences (GILD)

Howard Kim13 days ago

Insulet (PODD) Receives a Buy from Bernstein

TipRanks Auto-Generated Intelligence Newsdesk21 days ago

Wells Fargo Sticks to Their Buy Rating for Insulet (PODD)

TipRanks Auto-Generated Intelligence Newsdesk21 days ago

RBC Capital Sticks to Their Buy Rating for Insulet (PODD)

TipRanks Auto-Generated Intelligence Newsdeska month ago
ABCD
1SymbolPriceChangeVol
2PODD$256.62+0.3%1.07M
3
4
5
6

Get Insulet Corporation Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.